🇺🇸 Romiplostin in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 21

Most-reported reactions

1. Dizziness — 3 reports (14.29%)
2. Dyspnoea — 3 reports (14.29%)
3. Oedema Peripheral — 3 reports (14.29%)
4. Asthenia — 2 reports (9.52%)
5. Hyponatraemia — 2 reports (9.52%)
6. Neutropenia — 2 reports (9.52%)
7. Pancytopenia — 2 reports (9.52%)
8. Thrombocytopenia — 2 reports (9.52%)
9. Acute Graft Versus Host Disease In Skin — 1 report (4.76%)
10. Anaemia — 1 report (4.76%)

Source database →

Frequently asked questions

Is Romiplostin approved in United States?

Romiplostin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Romiplostin in United States?

Gruppo Italiano Malattie EMatologiche dell'Adulto is the originator. The local marketing authorisation holder may differ — check the official source linked above.